JP2018502898A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018502898A5 JP2018502898A5 JP2017539363A JP2017539363A JP2018502898A5 JP 2018502898 A5 JP2018502898 A5 JP 2018502898A5 JP 2017539363 A JP2017539363 A JP 2017539363A JP 2017539363 A JP2017539363 A JP 2017539363A JP 2018502898 A5 JP2018502898 A5 JP 2018502898A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- disease
- composition according
- disorder
- body weight
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims description 87
- UFBJCMHMOXMLKC-UHFFFAOYSA-N 2,4-dinitrophenol Chemical compound OC1=CC=C([N+]([O-])=O)C=C1[N+]([O-])=O UFBJCMHMOXMLKC-UHFFFAOYSA-N 0.000 claims description 41
- 230000037396 body weight Effects 0.000 claims description 38
- 239000000203 mixture Substances 0.000 claims description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 28
- 201000010099 disease Diseases 0.000 claims description 20
- 201000006417 multiple sclerosis Diseases 0.000 claims description 19
- 102000004219 Brain-derived neurotrophic factor Human genes 0.000 claims description 14
- 108090000715 Brain-derived neurotrophic factor Proteins 0.000 claims description 14
- 208000012239 Developmental disease Diseases 0.000 claims description 13
- 208000023275 Autoimmune disease Diseases 0.000 claims description 10
- 208000015122 neurodegenerative disease Diseases 0.000 claims description 10
- 150000003839 salts Chemical class 0.000 claims description 10
- 208000030159 metabolic disease Diseases 0.000 claims description 9
- 208000018360 neuromuscular disease Diseases 0.000 claims description 9
- 208000024891 symptom Diseases 0.000 claims description 9
- 208000023105 Huntington disease Diseases 0.000 claims description 8
- 208000003435 Optic Neuritis Diseases 0.000 claims description 8
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 8
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 8
- 208000029560 autism spectrum disease Diseases 0.000 claims description 8
- 206010028417 myasthenia gravis Diseases 0.000 claims description 8
- 230000004770 neurodegeneration Effects 0.000 claims description 8
- 239000006186 oral dosage form Substances 0.000 claims description 8
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 8
- 230000009529 traumatic brain injury Effects 0.000 claims description 8
- 208000035895 Guillain-Barré syndrome Diseases 0.000 claims description 7
- 206010049567 Miller Fisher syndrome Diseases 0.000 claims description 7
- 206010028289 Muscle atrophy Diseases 0.000 claims description 6
- 208000018737 Parkinson disease Diseases 0.000 claims description 6
- 206010015037 epilepsy Diseases 0.000 claims description 6
- 201000000585 muscular atrophy Diseases 0.000 claims description 6
- 230000006378 damage Effects 0.000 claims description 5
- 208000024827 Alzheimer disease Diseases 0.000 claims description 4
- 208000031277 Amaurotic familial idiocy Diseases 0.000 claims description 4
- 208000009575 Angelman syndrome Diseases 0.000 claims description 4
- 206010003591 Ataxia Diseases 0.000 claims description 4
- 208000023328 Basedow disease Diseases 0.000 claims description 4
- 206010013801 Duchenne Muscular Dystrophy Diseases 0.000 claims description 4
- 208000015023 Graves' disease Diseases 0.000 claims description 4
- 208000032382 Ischaemic stroke Diseases 0.000 claims description 4
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 4
- 208000007400 Relapsing-Remitting Multiple Sclerosis Diseases 0.000 claims description 4
- 208000006289 Rett Syndrome Diseases 0.000 claims description 4
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 4
- 238000013270 controlled release Methods 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 208000014188 hereditary optic neuropathy Diseases 0.000 claims description 4
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 4
- 230000006698 induction Effects 0.000 claims description 4
- 206010025135 lupus erythematosus Diseases 0.000 claims description 4
- 208000012268 mitochondrial disease Diseases 0.000 claims description 4
- 201000006938 muscular dystrophy Diseases 0.000 claims description 4
- 230000002232 neuromuscular Effects 0.000 claims description 4
- 206010063401 primary progressive multiple sclerosis Diseases 0.000 claims description 4
- 201000000980 schizophrenia Diseases 0.000 claims description 4
- 201000008628 secondary progressive multiple sclerosis Diseases 0.000 claims description 4
- 239000012453 solvate Substances 0.000 claims description 4
- 239000012730 sustained-release form Substances 0.000 claims description 4
- 206010061818 Disease progression Diseases 0.000 claims description 3
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 3
- 201000010769 Prader-Willi syndrome Diseases 0.000 claims description 3
- 208000027418 Wounds and injury Diseases 0.000 claims description 3
- 230000005750 disease progression Effects 0.000 claims description 3
- 208000014674 injury Diseases 0.000 claims description 3
- 230000032683 aging Effects 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 210000003169 central nervous system Anatomy 0.000 claims description 2
- 230000004064 dysfunction Effects 0.000 claims description 2
- 230000000694 effects Effects 0.000 claims description 2
- 230000000750 progressive effect Effects 0.000 claims description 2
- 230000000306 recurrent effect Effects 0.000 claims description 2
- 230000000472 traumatic effect Effects 0.000 claims description 2
- 208000035475 disorder Diseases 0.000 claims 8
- 238000009472 formulation Methods 0.000 claims 4
- 208000016097 disease of metabolism Diseases 0.000 claims 3
- 238000013268 sustained release Methods 0.000 claims 2
- 208000011580 syndromic disease Diseases 0.000 claims 2
- 208000006136 Leigh Disease Diseases 0.000 claims 1
- 208000017507 Leigh syndrome Diseases 0.000 claims 1
- 238000000034 method Methods 0.000 description 24
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021031635A JP7440092B2 (ja) | 2015-01-22 | 2021-03-01 | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562106365P | 2015-01-22 | 2015-01-22 | |
| US62/106,365 | 2015-01-22 | ||
| PCT/US2016/014312 WO2016118741A1 (en) | 2015-01-22 | 2016-01-21 | Induced expression of brain derived neurotrophic factor (bdnf) for treatment of neuromuscular, neurodegenerative, autoimmune, developmental and/or metabolic diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031635A Division JP7440092B2 (ja) | 2015-01-22 | 2021-03-01 | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018502898A JP2018502898A (ja) | 2018-02-01 |
| JP2018502898A5 true JP2018502898A5 (https=) | 2019-02-28 |
| JP6951976B2 JP6951976B2 (ja) | 2021-10-20 |
Family
ID=55310938
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017539363A Active JP6951976B2 (ja) | 2015-01-22 | 2016-01-21 | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 |
| JP2021031635A Active JP7440092B2 (ja) | 2015-01-22 | 2021-03-01 | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 |
| JP2022159466A Pending JP2022173519A (ja) | 2015-01-22 | 2022-10-03 | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021031635A Active JP7440092B2 (ja) | 2015-01-22 | 2021-03-01 | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 |
| JP2022159466A Pending JP2022173519A (ja) | 2015-01-22 | 2022-10-03 | 神経筋疾患、神経変性疾患、自己免疫疾患、発達疾患および／または代謝疾患の処置のための、脳由来神経栄養因子（ｂｄｎｆ）の誘導された発現 |
Country Status (13)
| Country | Link |
|---|---|
| US (6) | US9763896B2 (https=) |
| EP (2) | EP4306167B1 (https=) |
| JP (3) | JP6951976B2 (https=) |
| KR (1) | KR102690198B1 (https=) |
| CN (2) | CN107405315A (https=) |
| AU (2) | AU2016209255B2 (https=) |
| BR (1) | BR112017015721A2 (https=) |
| CA (1) | CA2974092A1 (https=) |
| ES (2) | ES2961334T3 (https=) |
| HK (1) | HK1247101A1 (https=) |
| MX (2) | MX392410B (https=) |
| PT (1) | PT3247340T (https=) |
| WO (1) | WO2016118741A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107405315A (zh) | 2015-01-22 | 2017-11-28 | 米托充制药公司 | 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 |
| WO2018129258A1 (en) | 2017-01-06 | 2018-07-12 | Gencia Corporation | Novel phenyl derivatives |
| AU2018215056A1 (en) * | 2017-01-31 | 2019-08-08 | Charles E. Inturrisi | D-methadone and its derivatives for use in the treatment of disorders of the nervous system |
| CA3061201A1 (en) | 2017-06-23 | 2018-12-27 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US10660879B2 (en) | 2017-06-23 | 2020-05-26 | Enzo Biochem, Inc. | Sphingosine pathway modulating compounds for the treatment of cancers |
| US20210393621A1 (en) | 2018-10-26 | 2021-12-23 | The Research Foundation For The State University Of New York | Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia |
| EP4223307A4 (en) * | 2020-09-29 | 2024-07-24 | Cefo Co., Ltd. | COMPOSITION FOR THE PREVENTION OR TREATMENT OF A NEUROPSYCHOLOGICAL DISEASE, COMPRISING MANF |
| WO2023205625A2 (en) * | 2022-04-18 | 2023-10-26 | Mitochon Pharmaceuticals, Inc. | 2,4 dnp and prodrugs thereof for treatment of pulmonary and autoimmune diseases |
| WO2025051360A1 (en) * | 2023-09-06 | 2025-03-13 | Instituto de Medicina Molecular João Lobo Antunes | Trkb-t1 agonist for the treatment of absence seizure and/or comorbidities |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6664297B1 (en) * | 2000-10-18 | 2003-12-16 | Universidade Federal Do Rio De Janeiro | Methods for inhibition and dissolution of amyloidoses by administration of compositions comprising 2,4-dinitrophenol |
| US7135575B2 (en) * | 2003-03-03 | 2006-11-14 | Array Biopharma, Inc. | P38 inhibitors and methods of use thereof |
| EP1764095A1 (en) * | 2005-09-20 | 2007-03-21 | Revotar Biopharmaceuticals AG | Novel nitrocatechol derivatives having selectin ligand activity |
| US20100130597A1 (en) | 2007-07-06 | 2010-05-27 | The United State Of America, As Represented By The Secretary Of The Dept Of Health And Human Service | Dna-pkcs modulates energy regulation and brain function |
| WO2015031756A1 (en) * | 2013-08-30 | 2015-03-05 | Yale University | Novel 2,4-dinitrophenol formulations and methods using same |
| CN107405315A (zh) * | 2015-01-22 | 2017-11-28 | 米托充制药公司 | 用于治疗神经肌肉、神经变性、自身免疫、发育和/或代谢疾病的脑源性神经营养因子(bdnf)的诱导表达 |
-
2016
- 2016-01-21 CN CN201680017379.4A patent/CN107405315A/zh active Pending
- 2016-01-21 CA CA2974092A patent/CA2974092A1/en active Pending
- 2016-01-21 CN CN202211548767.9A patent/CN116617195A/zh active Pending
- 2016-01-21 EP EP23188878.5A patent/EP4306167B1/en active Active
- 2016-01-21 AU AU2016209255A patent/AU2016209255B2/en active Active
- 2016-01-21 ES ES16703409T patent/ES2961334T3/es active Active
- 2016-01-21 ES ES23188878T patent/ES3057870T3/es active Active
- 2016-01-21 EP EP16703409.9A patent/EP3247340B1/en active Active
- 2016-01-21 HK HK18106712.4A patent/HK1247101A1/zh unknown
- 2016-01-21 WO PCT/US2016/014312 patent/WO2016118741A1/en not_active Ceased
- 2016-01-21 US US15/002,531 patent/US9763896B2/en active Active
- 2016-01-21 PT PT167034099T patent/PT3247340T/pt unknown
- 2016-01-21 BR BR112017015721A patent/BR112017015721A2/pt not_active Application Discontinuation
- 2016-01-21 KR KR1020177023034A patent/KR102690198B1/ko active Active
- 2016-01-21 MX MX2017009402A patent/MX392410B/es unknown
- 2016-01-21 JP JP2017539363A patent/JP6951976B2/ja active Active
- 2016-11-21 US US15/357,412 patent/US9974755B2/en active Active
-
2017
- 2017-07-18 MX MX2022005937A patent/MX2022005937A/es unknown
- 2017-09-18 US US15/707,239 patent/US10220006B2/en active Active
-
2019
- 2019-01-17 US US16/250,470 patent/US10864173B2/en active Active
-
2020
- 2020-11-09 US US17/093,193 patent/US11717497B2/en active Active
-
2021
- 2021-03-01 JP JP2021031635A patent/JP7440092B2/ja active Active
- 2021-09-27 AU AU2021240120A patent/AU2021240120A1/en not_active Abandoned
-
2022
- 2022-10-03 JP JP2022159466A patent/JP2022173519A/ja active Pending
-
2023
- 2023-06-16 US US18/336,440 patent/US20240156750A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018502898A5 (https=) | ||
| WO2021162532A3 (ko) | Glp-1 유사체, 또는 이의 약학적으로 허용가능한 염을 포함하는 서방형 미립구를 포함하는 약학적 조성물 | |
| JP2018520189A5 (https=) | ||
| JP2021530541A5 (https=) | ||
| JP2018529742A5 (https=) | ||
| JP2015528471A5 (https=) | ||
| JP2015512406A5 (https=) | ||
| JP2016512531A5 (https=) | ||
| JP2009536176A5 (https=) | ||
| JP2012111764A5 (https=) | ||
| JP2015510916A5 (https=) | ||
| JP2018516992A5 (https=) | ||
| JP2018537513A5 (https=) | ||
| JP2018527305A5 (https=) | ||
| JP2020533296A5 (https=) | ||
| JP2016537432A5 (https=) | ||
| JP2018199643A5 (https=) | ||
| JP2016512247A5 (https=) | ||
| IL272834B1 (en) | Compositions of amantadine, their preparation, and methods of use | |
| JP2019507786A5 (https=) | ||
| JP2019531286A5 (https=) | ||
| JP2016537431A5 (https=) | ||
| JP2013544795A5 (https=) | ||
| JP2020509072A5 (https=) | ||
| JP2019516726A5 (https=) |